Introduction

48
VZV is the first human herpesvirus for which a vaccine has been licensed. In 1995, the 49 US became the first country to implement routine varicella vaccination for healthy children aged 50 12 to 18 months (12), resulting in a dramatic decline in varicella morbidity and mortality (9, 33).
51
More recently, a higher dose formulation of the same vaccine seed virus was licensed and 52 recommended for the prevention of HZ in persons ≥60 years of age (4) 53 Differentiation of vOka from wt virus has become important for at least two reasons.
54
Testing can be used to assess vOka effectiveness by identifying cases of breakthrough varicella 55 caused by wt virus. Breakthrough disease occurred in 3-25% of vOka recipients in outbreak 56 settings (5, 22, 50) and is several-fold more likely to occur among vOka recipients with low 57 VZV IgG levels 6 weeks post-vaccination (<5 gpELISA U/mL) (22, 33)). Strain discrimination 58 testing is also used to document adverse events associated with vOka. Serious adverse events due 59 to vOka are rare, with only 8 laboratory-confirmed reports of meningitis or encephalitis (6, 7, 12, 60 17, 26, 27, 32, 37) and 7 cases of secondary transmission (13, 17, 18, 24) . One of the most 61 common complications post-immunization is a varicella-like rash that occurs, within 1 to 6 62 weeks post-immunization (6, 17, 43). The incidence of rash is approximately 5% in healthy 63 children (14, 49) . vOka can also establish latency and reactivate to cause HZ. While the 64 incidence of wt HZ after vaccination has declined (8, 19, 25, 50) , the incidence of HZ caused by 65 vOka is less well defined as most recipients of the vaccine are children, in whom HZ (vOka or 66 wt) is uncommon. In addition, very few HZ cases occurring post-vaccination are identified as 67 attributable to vOka versus wt by laboratory testing.
68
vOka is a live attenuated virus produced by serial passage of, pOka, in tissue culture (46) .
69
Three preparations of vOka are in commercial production, vOka/Biken (Biken Institute, Japan), 
85
Five confirmed and 2 provisional wt VZV clades have been described, ( respectively were characterized using an in-house FRET-based realtime PCR assay. SNPs in
171
ORFs 1, 21, 22 and 50 were analyzed by PCR and sequencing as previously described (1, 29) .
172
PCR amplification of the entire ORF 62 (4087bp) was performed using a forward (5`-
173
CCCGCACAGACAGACAGACACT-3`) and reverse (5`-CTGCGAGAGCGTTTGGAAAACT- 
Statistical Calculations
224
We estimated the probability of occurrence of the wt allele as the number of variant (i.e. wt)
225
alleles that we found divided by the total number of sequences that we analyzed. We assumed a 226 binomial distribution to obtain a 95% confidence interval for the probability, using the calculator cases that had been transmitted from an 86-year-old HZ patient in a long-term care facility (31).
296
Since the index case patient would likely have experienced her primary infection in childhood, ORF38 will also be needed to determine whether an isolate has the SNP profile of vOka-like 322 clade 2 strains.
323
We initially screened position 107252 using RFLPs generated by Nae1 restriction 324 endonuclease. We demonstrated that this approach is a robust, rapid and cost effective screening 325 tool for characterization of this locus through RFLP patterns generated from the entire OFR62 326 fragment. The consistency of the additional Nae1 sites in all vOka genomes makes this method 327 applicable to the analysis of all batches of vOka.
328
Our observation of a case of vOka HZ illustrates the need for a more complex approach 
347
Another concern for diagnostic approaches to discriminating between vOka and wt 348 strains is the possibility of recombination between vOka and wt virus in co-infected persons.
349
Recombination between wt VZV strains has been reported in vitro and in vivo (1, 2, 11) 
